An evaluation of inhibin and activin as early markers of pre-eclampsia and fetal growth restriction.

Funded Activity Summary

Pre-eclampsia and fetal growth problems are among the major causes of maternal and perinatal death in Australia. One of the most pressing difficulties in the management of these conditions is our present inability to accurately predict those women who are destined to have one or other of these serious complications. Unfortunately, this means that the conditions are often detected late with little or no time to offer effective treatments. This project builds on exciting preliminary evidence that suggests that a simple blood test from the mother in early pregnancy may be able to identify the women who will subsequently develop high blood pressure in late pregnancy, or the babies that will suffer impaired growth before delivery. In the future, such knowledge might then allow these women to receive more effective care, thereby improving their chance of a successful pregnancy. The project will also define the best time in pregnancy to perform the blood test and, if successful, could alter the very way women are currently looked after during their pregnancy.

Funded Activity Details

Start Date: 01-01-2000

End Date: 01-01-2002

Funding Scheme: NHMRC Project Grants

Funding Amount: $96,921.00

Funder: National Health and Medical Research Council

Research Topics

ANZSRC Field of Research (FoR)

Obstetrics And Gynaecology

ANZSRC Socio-Economic Objective (SEO)

There are no SEO codes available for this funding activity

Other Keywords

Activin | Biochemical markers of disease | Fetal growth | Inhibin | Pre-eclampsia | Pregnancy complications | Pregnancy outcome

Related Links